Enlightening light chain deposition disease

Research output: Contribution to journalArticlepeer-review


In this issue of Blood, Sayed et al report on a series of 53 patients with light chain (LC) deposition disease (LCDD) prospectively followed for a median of 6.2 years, showing divergent outcomes in patients who achieve a very good partial response (VGPR) or complete response (CR) compared with those who do not (see figure, panel A). Even patients with advanced chronic kidney disease (CKD) benefited from a deep clonal response.

Original languageEnglish
Pages (from-to)2770-2771
Number of pages2
Issue number26
Publication statusPublished - Dec 24 2015

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology


Dive into the research topics of 'Enlightening light chain deposition disease'. Together they form a unique fingerprint.

Cite this